Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275.
Matthew D GalskyAbdel SaciPeter M SzaboG Celine HanGary GrossfeldSandra ColletteArlene Siefker-RadtkeAndrea NecchiPadmanee SharmaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
These results support the durable antitumor activity of nivolumab and suggest that TMB may enrich for better response in mUC. Future studies of TMB/PD-L1 as biomarkers for response to nivolumab in randomized trials are warranted.See related commentary by Swami et al., p. 5059.
Keyphrases